Robust analytical characterization is critical to the successful development of ADCs, from early screening to regulatory submissions. Due to their complex and heterogeneous nature, ADCs demand a specialized, multi-dimensional analytical strategy to evaluate purity, conjugation efficiency, drug-to-antibody ratio (DAR), aggregation, and stability. At Aurigene, we bring together cutting-edge instrumentation, methods, and a cross-functional scientific team to deliver a complete picture of your ADC molecule. Our analysis is not just about checking boxes. It's about generating actionable insights to guide your development decisions with confidence.

Quantifies average DAR and heterogeneity across the ADC population
Confirms successful conjugation, C-terminal lysine clipping, and pyroglutamate formation
Evaluates product purity, aggregation, and high-molecular-weight species
Determines exact sites of payload attachment and conjugation stoichiometry
Predicts shelf-life and storage conditions of ADCs
Aurigene stands out as a one-stop partner with deep analytical expertise tailored for ADCs. Our approach integrates bioconjugation chemistry, protein analytics, and mass spectrometry to deliver comprehensive characterization in a regulatory-ready format. With access to state-of-the-art instruments and advanced techniques, we don't just measure, we interpret. Our scientists provide meaningful analysis and recommendations that inform your decision-making across early development, formulation, and stability studies.
Integrated analytics from early conjugation through IND
Customizable analysis panels based on ADC format and phase
Fast turnaround times with high-quality data packages
Flexible support for standard mAbs, bispecific ADCs, antibody-oligo conjugates, and more
With Aurigene, you gain more than data, you gain a scientific partner invested in the quality, safety, and success of your ADC program.
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read MoreYou are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market